Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central theme at the recent Quarter Century Update conference, where leading experts like Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, illuminated how AI is [...]
Eli Lilly and Company (NYSE:LLY) shares are trading slightly lower on Tuesday after its previous gains following reports indicating the company is close to finalizing a White House agreement to provide its lowest-dose obesity medications at $149 per month, which could open the door to Medicare coverage and broader reimbursement options.
While the pharma giant Eli Lilly has lagged behind the broader market over the past year, it has outpaced the health care space, and analysts remain strongly bullish on the stock’s prospects.
Hims & Hers Health (NYSE: HIMS) became a significant after-hours mover on Monday, November 3, 2025, following the release of its third-quarter 2025 financial results and the pivotal announcement of renewed discussions with Novo Nordisk A/S (NYSE: NVO) regarding the potential distribution of Wegovy. While the telehealth platform reported a
Discover Eli Lilly (LLY), a dividend stock with a 10+ year payment history, 15.59% average growth, strong profitability, and solid financial health for reliable income.
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN)
will be reporting earnings this Tuesday after market hours. Here’s what you need to know.
